Alveo
Alameda, US · Founded 2015 · Delaware corporation · 66 employees on LinkedIn · 6 known investors
Find your way into Alveo
581 people in our graph share verified history with the Alveo team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Ron Chiarello · together at Stanford University (overlapped)
.jpeg)
×11knows the team · via Stanford University
Alveo Technologies makes a palm-sized molecular diagnostic analyzer with preloaded test cartridges that deliver on-site pathogen results in under an hour, with results sent to a smartphone. It targets point-of-need infectious disease detection, including avian influenza testing for poultry farms and workers.
Founders & leadership
Alveo was founded in 2015 by Ron Chiarello.
RC
Ron ChiarelloinFounder, Board Chair and CEO2015–2021Ron Chiarello is a physicist with background from Argonne and Stanford who has spent two decades building companies in diagnostics, biotech, AI, and quantum hardware, with cumulative fundraising exceeding $250 million and an XPRIZE award.
MA
Michael AicherExecutive
SH
Shaun HoltChairman of the Board & Chief Executive Officer
ET
Erik Tyrrell-KnottinPresident & Chief Business Officer
S
ScottChief Commercial Officer
SE
Slava ElagininExecutive (R&D/Operations)
M
MarcusSenior Vice President of Software Engineering
Board
IB
Isaac BlechBoard director
RS
Robin SteeleBoard director
LB
Lawrence BlattBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$63.6M disclosed across 2 rounds · 2016–2021
▶$16MraisedMar 2021 · 2 investors · BiotechnologyRule 506(b)
▶$16MraisedMar 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ronald ChiarelloExecutive Officer, Director
- Robin SteeleDirector
- Lawrence BlattDirector
- Julianne AverillExecutive Officer
- Yuh-Min ChiangExecutive Officer
- Nicholas BrathwaiteDirector
- Offering amount
- $30.1M
- Amount sold
- $16M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$47.6MraisedFeb 2018 · 248 investors · BiotechnologyRule 506(b)
▶$47.6MraisedFeb 2018 · 248 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac BlechDirector
- Robin SteeleDirector
- Michael AicherExecutive Officer, Director
- Ron ChiarelloExecutive Officer, Director
- Lawrence BlattDirector
- Offering amount
- $47.6M
- Amount sold
- $47.6M
- Sales commissions
- $3.1M
- Placement agents
- Maxim Group LLC
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Cerecor Inc.6 shared keywordsAvalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.
Labcorp5 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Alveolusbio5 shared keywordsAlveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD. It serves patients with chronic and infectious respiratory conditions in the biotechnology and pharmaceutical space.
Companies competing with Alveo for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Alveo do?
- Alveo Technologies makes a palm-sized molecular diagnostic analyzer with preloaded test cartridges that deliver on-site pathogen results in under an hour, with results sent to a smartphone. It targets point-of-need infectious disease detection, including avian influenza testing for poultry farms and workers.
- Who founded Alveo?
- Alveo was founded by Ron Chiarello in 2015.
- Who are Alveo's investors?
- Alveo's investors include Black Diamond Ventures, Celesta Capital, Celesta Capital, Civilization Ventures Management, Llc, Partners Resolute, SUPPLY CHANGE CAPITAL.
- How much funding has Alveo raised?
- Alveo has disclosed $63.6M raised across 2 rounds.
- Where is Alveo headquartered?
- Alveo is headquartered in Alameda, US.